Skip to main content Accessibility help
×
Home
Hostname: page-component-544b6db54f-lmg95 Total loading time: 0.323 Render date: 2021-10-22T01:17:39.689Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Article contents

Presence and evolution of a new psychoactive tryptamines branch

Published online by Cambridge University Press:  23 March 2020

Á. Palma Conesa*
Affiliation:
Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, Psychiatry, Barcelona, Spain Institut Hospital del Mar d’Investigacions Mèdiques, IMIM, Parc de Salut Mar, Psychiatry, Barcelona, Spain
L. Galindo Guarin
Affiliation:
Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, Psychiatry, Barcelona, Spain
M. Grifell Guardia
Affiliation:
Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, Psychiatry, Barcelona, Spain Institut Hospital del Mar d’Investigacions Mèdiques, IMIM, Parc de Salut Mar, Psychiatry, Barcelona, Spain
P. Quintana Mathe
Affiliation:
Energy Control, Asociación Bienestar y Desarrollo, Energy Control, Barcelona, Spain
C. Gil Lladanosa
Affiliation:
Energy Control, Asociación Bienestar y Desarrollo, Energy Control, Barcelona, Spain
I. Fornís Espinosa
Affiliation:
Energy Control, Asociación Bienestar y Desarrollo, Energy Control, Barcelona, Spain
M. Ventura Vilamala
Affiliation:
Energy Control, Asociación Bienestar y Desarrollo, Energy Control, Barcelona, Spain
M. Torrens Melich
Affiliation:
Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, Psychiatry, Barcelona, Spain Institut Hospital del Mar d’Investigacions Mèdiques, IMIM, Parc de Salut Mar, Psychiatry, Barcelona, Spain Universitat Autònoma de Barcelona, Psychiatry, Barcelona, Spain
M. Farré Albaladejo
Affiliation:
Universitat Autònoma de Barcelona, Psychiatry, Barcelona, Spain Servei de Farmacología Clínica, Hospital Germans Trías i Pujol, Clinical Farmacology, Barcelona, Spain
M.F. Fonseca Casals
Affiliation:
Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, Psychiatry, Barcelona, Spain Institut Hospital del Mar d’Investigacions Mèdiques, IMIM, Parc de Salut Mar, Psychiatry, Barcelona, Spain
*
* Corresponding author.
Get access

Abstract

Introduction

New psychoactive substances (NPS) are substances that have recently appeared on the market and are not under international control. NPS use is experiencing an unprecedented increase. DiPT, 4-HO-DiPT and 4-AcO-DiPT are new psychoactive tryptamines and their effects may differ from those of other psychoactive tryptamines.

Objective

To explore the presence of DiPT, 4-HO-DiPT and 4-AcO-DiPT from samples delivered to and analyzed by Spanish harm reduction service Energy Control.

Materials and methods

All samples analyzed from 2009 to 2014 delivered as DiPT, 4-HO-DiPT and 4-AcO-DPT or containing these substances. Analysis was performed by gas chromatography–mass spectrometry.

Results

From 17,432 samples, 4-HO-DiPT was found in 16, delivered as 4-HO-DiPT (6); 4-AcO-DiPT (7); DiPT (1); 4-AcO-DMT (1) and cocaine (1). 4-AcO-DiPT was found in 16, delivered as 4-AcO-DiPT (12); 5-MeO-DMT (1); 5-MeO-DiPT (1); 4-AcO-DMT (1) and cocaine (1). Only 4 samples contained DiPT, all presented as DiPT. Nine samples contained both 4-AcO-DiPT and 4-HO-DiPT. During the years of study, 4-HO-DiPT deliverance was increasing (4 samples in 2014) while deliverance of 4-AcO-DiPT and DiPT was decreasing (1 sample in 2014).

Conclusions

Increasing 4-HO-DiPT presence could translate a progressive replacement of 4-AcO-DiPT and DiPT recreational use. Clinical relevance comes from its growing use and the absence of scientific evidence on humans, therefore relying on users subjective experience to predict the effects.

Disclosure of interest

The authors declare that they have no competing interest.

Type
EW13
Copyright
Copyright © European Psychiatric Association 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
Submit a response

Comments

No Comments have been published for this article.

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Presence and evolution of a new psychoactive tryptamines branch
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Presence and evolution of a new psychoactive tryptamines branch
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Presence and evolution of a new psychoactive tryptamines branch
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *